# US 2014/0193815 A1 · Methods of using oligonucleotides comprising a molecular switch > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193815 A1 - Document ID: US20140193815A1 - Status: Published application - Kind: A1 - Application number: 14/153,261 - Filed: 2014-01-13 - Published: 2014-07-10 - Earliest claimed: 2003-05-01 - Assignees: Gen-Probe Incorporated - Applicants: Gen-Probe Incorporated - Inventors: Lyle J. Arnold, JR.; Bob D. Brown - Web page: https://patentgrep.com/patent/US20140193815A1 ## CPC - C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase - C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence) - C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer - C12Q 1/6827: for detection of mutation or polymorphism - C12Q 1/6858: Allele-specific amplification - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract This invention relates to oligonucleotides comprising a molecular switch which may exist in an “open” or “closed” position. The molecular switch portion of the probe is particularly sensitive to the identity of sequences complementary to the molecular switch. Oligonucleotides containing a molecular switch are applicable to all kinds of hybridization processes. Due to the sensitivity of the switch domain of the oligonucleotide, probes containing a molecular switch are particularly useful in the identification of single point mismatches. More specifically, a portion, but not all, of the oligonucleotide becomes unbound from a mismatched target. The invention further relates to methods of using said oligonucleotides for research reagents, and clinical diagnostics. An exemplary oligonucleotide comprises a first hybridizable domain, a second bridging block domain, and a third binding domain. ## Claims ### Claim 1 A method of detecting the presence or absence of a mutation or polymorphism in a sample comprising nucleic acids, the method comprising: (1) contacting said sample, under conditions suitable for hybridization, with an oligonucleotide comprising (a) a nucleic acid anchor region complementary to a first sequence of nucleic acid residues of a target nucleic acid, and (b) a switch domain comprising a bridging domain and a binding domain, wherein said binding domain comprises 2-20 nucleic acid bases or analogs thereof complementary to said target nucleic acid and said binding domain has less affinity for said target nucleic acid than said anchor region, wherein said bridging domain is located between said anchor region and said binding domain and comprises 2-11 universal, generic or mismatched natural bases or analogs thereof or a mixture of universal and non-hydrogen bonding natural bases that do not form a Watson-Crick hybridization complex with said target nucleic acid, wherein two or more universal or non-hydrogen bonding natural bases or analogs thereof or a mixture of universal and non-hydrogen bonding natural bases in said bridging domain are juxtaposed, and wherein said universal or non-hydrogen bonding natural bases in said bridging domain substitute for bases complementary to nucleotide bases of said target nucleic acid, and wherein said switch domain is able to discriminate between (i) a sequence of nucleic acid residues of said target nucleic acid that is complementary to said binding domain and (ii) a second mismatch sequence of nucleic acid residues of said target nucleic acid that contains at least one nucleic acid residue that is not complementary to said binding domain, under conditions wherein said anchor region (a) forms a stable duplex with said first sequence of nucleic acid residues of said target nucleic acid, wherein the at least one nucleic acid residue that is not complementary to said binding domain corresponds to the site of the polymorphism or mutation to be detected; and (2) determining, under the conditions wherein said anchor region (a) forms the stable duplex with said first sequence, the hybridization status of said switch domain as an indication of the presence or absence of the mutation or polymorphism in said sample. ### Claim 2 (depends on 1) The method of claim 1, wherein said oligonucleotide further comprises a detectable label and the amount of signal detected from the detectable label is determinative of the hybridization status of said switch domain. ### Claim 3 (depends on 2) The method of claim 2, wherein the detectable label is a fluorescent label. ### Claim 4 (depends on 3) The method of claim 3, wherein said oligonucleotide further comprises a quencher, wherein the quencher and the fluorescent label interact to modulate the amount of signal detected from the fluorescent label. ### Claim 5 (depends on 4) The method of claim 4, further comprising monitoring the hybridization status of said anchor region with said first sequence, wherein said oligonucleotide further comprises a second fluorescent label and the amount of signal detected from the second fluorescent label is determinative of the hybridization status of said anchor region. ### Claim 6 (depends on 2) The method of claim 2, wherein the amount of signal detected from the detectable label is decreased when the switch domain is not hybridized to said target nucleic acid, relative to the amount of signal detected from the detectable label when the switch domain is hybridized to said target nucleic acid. ### Claim 7 (depends on 2) The method of claim 2, wherein said oligonucleotide further comprises a first fluorescent label and a second fluorescent label, wherein the first and second fluorescent labels interact to modulate the amount of signal detected from the first and/or second fluorescent label dependent on the hybridization status of said switch domain. ### Claim 8 (depends on 1) The method of claim 1, wherein the target nucleic acid is associated with a disease or condition. ### Claim 9 (depends on 1) The method of claim 1, wherein the target nucleic acid is associated with an infectious organism. ### Claim 10 (depends on 1) The method of claim 1, wherein the method is for detecting the presence or absence of the polymorphism, and wherein the polymorphism is a single nucleotide polymorphism (SNP). ### Claim 11 A method of genotyping a target nucleic acid in a sample, the method comprising: (1) contacting said sample, under conditions suitable for hybridization, with first and second oligonucleotides, each of said first and second oligonucleotides comprising (a) a nucleic acid anchor region complementary to a first sequence of nucleic acid residues of the target nucleic acid, and (b) a switch domain comprising a bridging domain and a binding domain, wherein said binding domain comprises 2-20 nucleic acid bases or analogs thereof complementary to said target nucleic acid and said binding domain has less affinity for said target nucleic acid than said anchor region, wherein said bridging domain is located between said anchor region and said binding domain and comprises 2-11 universal, generic or mismatched natural bases or analogs thereof or a mixture of universal and non-hydrogen bonding natural bases that do not form a Watson-Crick hybridization complex with said target nucleic acid, wherein two or more universal or non-hydrogen bonding natural bases or analogs thereof or a mixture of universal and non-hydrogen bonding natural bases in said bridging domain are juxtaposed, and wherein said universal or non-hydrogen bonding natural bases in said bridging domain substitute for bases complementary to nucleotide bases of said target nucleic acid, and wherein said switch domain is able to discriminate between (i) a sequence of nucleic acid residues of said target nucleic acid that is complementary to said binding domain and (ii) a second mismatch sequence of nucleic acid residues of said target nucleic acid that contains at least one nucleic acid residue that is not complementary to said binding domain, under conditions wherein said anchor region (a) forms a stable duplex with said first sequence of nucleic acid residues of said target nucleic acid, wherein the at least one nucleic acid residue that is not complementary to said binding domain corresponds to the site of a polymorphism or mutation to be detected; wherein the first and second oligonucleotides form a tandem oligonucleotide assembly in which the first and second oligonucleotides are positioned side-by-side when hybridized to the target nucleic acid, and wherein a first detectable label is associated with the first oligonucleotide and a second detectable label is associated with the second oligonucleotide, wherein the amount of signal detectable from said first and/or said second detectable label is altered when the binding domain of each of said first and second oligonucleotides is hybridized to the target nucleic acid, relative to the amount of signal detectable from said first and/or said second detectable label when either binding domain is hybridized to said target nucleic acid individually; and (2) determining, under the conditions wherein each anchor region (a) forms the stable duplex with the respective first sequence, the hybridization status of each switch domain as an indication of the presence or absence of the mutation or polymorphism corresponding to each binding domain, thereby genotyping the target nucleic acid. ### Claim 12 (depends on 11) The method of claim 11, wherein the binding domain of said first oligonucleotide and said second oligonucleotide hybridize at least in part with overlapping regions of the target nucleic acid. ### Claim 13 (depends on 11) The method of claim 11, wherein the first oligonucleotide is attached to a solid support. ### Claim 14 (depends on 11) The method of claim 11, wherein the first and second detectable labels are both fluorescent labels, wherein the first fluorescent label transfers energy non-radiatively to the second fluorescent label when the binding domains of said first and second oligonucleotides are both hybridized to said target nucleic acid, and wherein determining the hybridization status of each switch domain comprises measuring energy transfer from the first fluorescent label to the second fluorescent label. ### Claim 15 (depends on 11) The method of claim 11, wherein the first and second detectable labels are both fluorescent labels, and wherein each of said first and second oligonucleotides further comprises a quenching label such that when the switch domain of the said first or second oligonucleotide is associated with an unmatched target the quenching label reduces the fluorescence intensity of the respective first or second fluorescent label. ### Claim 16 (depends on 11) The method of claim 11, wherein the first and second detectable labels are both fluorescent labels, such that when the switch domain of said first oligonucleotide is associated with a matched target, fluorescent energy transfer between the first and second fluorescent labels is enhanced, and when the switch domain of said second oligonucleotide is associated with a matched target the fluorescent energy transfer between the first and second fluorescent labels is reduced. ### Claim 17 (depends on 11) The method of claim 11, wherein the first and second detectable labels are both chemiluminescent labels ### Claim 18 (depends on 17) The method of claim 17, wherein the first and second chemiluminescent labels are separately detectable acridinium esters. ### Claim 19 (depends on 18) The method of claim 18, wherein the first and second chemiluminescent acridinium esters have differing rates of photo-emission. ### Claim 20 (depends on 18) The method of claim 18, wherein the wavelength of light emitted by the first and second chemiluminescent acridinium esters is used to determine the hybridization status of each switch domain.